Evidence map›Paper›PMID 27261455›Full record

ArticleIntegrative cancer therapies2017

Comprehensive and Holistic Analysis of HT-29 Colorectal Cancer Cells and Tumor-Bearing Nude Mouse Model: Interactions Among Fractions Derived From the Chinese Medicine Formula Tian Xian Liquid in Effects on Human Colorectal Carcinoma.

Annballaw Bridget Leigh, Ho Pan Cheung, Li-Zhu Lin, Tzi Bun Ng, Lixing Lao, Yanbo Zhang, Zhang-Jin Zhang, Yao Tong, Stephen Cho Wing Sze

Open access · goldAbstract read
In one paragraph

Article in Integrative cancer therapies, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Annballaw Bridget Leigh1 The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Ho Pan Cheung1 The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Li-Zhu Lin2 First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Tzi Bun Ng3 The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China.
Lixing Lao1 The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Yanbo Zhang1 The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Zhang-Jin Zhang1 The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Yao Tong1 The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Stephen Cho Wing Sze1 The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
University of Hong Kong · HKChinese University of Hong Kong · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Chinese medicine formula Tian Xian Liquid (TXL) has been used clinically for cancer therapy in China for more than 25 years. However, the comprehensive and holistic effects of its bioactive fractions for various antitumor therapeutic effects have not been unraveled. This is the first study to scientifically elucidate the holistic effect of Chinese medicine formula for treating colon cancer, hence allowing a better understanding of the essence of Chinese medicine formula, through the comparison of the actions of TXL and its functional constituent fractions, including ethyl acetate (EA), butanol (BU), and aqueous (WA) fractions. Tissue-specific proliferative/antiproliferative effects of these fractions on human colorectal carcinoma HT-29 cells and splenocytes were studied by using the MTT assay. Their modulations on the expression of markers of antiproliferation, antimetastasis, reversion of multidrug resistance in treated HT-29 cells were examined with real-time polymerase chain reaction and Western blot analysis, and their modulations in a xenografted nude mouse model were examined by Western blot analysis. Results revealed that EA fraction slightly inhibited the proliferation of HT-29 cells, but tissue-specifically exerted the most potent antiproliferative effect on splenocytes. On the contrary, only TXL and BU fraction tissue-specifically contributed to the proliferation of splenocytes, but inhibited the proliferation of HT-29 cells. WA fraction exerted the most potent antiproliferative effect on HT-29 cells and also the strongest inhibitory action on tumor size in the nude mouse model in our previous study. In the HT-29 model, TXL and WA fraction exerted the most pronounced effect on upregulation of p21 mRNA and protein; TXL, and EA and WA fractions exerted the effect on downregulation of G1 phase cell cycle protein, cyclin D1 mRNA and protein; EA and BU fractions exerted the most prominent anti-invasive effect on anti-invasion via downregulation of MMP-1 mRNA; TXL potently reversed most multidrug resistance via downregulation of MDR-1 protein. In conclusion, the comprehensive and holistic effects of TXL were demonstrated with ( a) mutual accentuation and mutual enhancement, ( b) mutual counteraction and mutual suppression, and ( c) mutual antagonism among the 3 constituent fractions. Moreover, the design of the present study may lead to further development of more tissue-specific effective drugs with minimal side effects for clinical use in combating carcinoma.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicApoptosisCarcinomaCell Line, TumorCell ProliferationColorectal NeoplasmsDown-RegulationDrugs, Chinese HerbalFemaleG1 PhaseHT29 CellsHumansMedicine, Chinese TraditionalMiceMice, NudeAntineoplastic Agents, PhytogenicDrugs, Chinese Herbaltian-xianantitumorigenicityChinese medicinal formulacolon cancerconstituent fractionsholisticTian Xian Liquid

Identifiers

PMID27261455
PMCPMC5759938
OpenAlexW2417875440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.